Insider Purchases: Inside the Buy
Tag: BiotechInvesting

Healthpeak Properties (DOC): Insiders Are Buying—Should You?
📈 Healthpeak Properties (DOC) insiders are buying—and not just a little. But with a forward P/E north of 70 and a few post-merger integration challenges, is this stock still a hidden gem or more of a polished maybe? Dive in for the full take.

Quanterix Insiders Are Buying. Should You?
Quanterix insiders are buying, and institutions are still in. But revenue is sliding, and losses are deep. A potential comeback or another biotech burn? 🔬💸

Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!
Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?
Quick links
Search
Privacy Policy
Refund Policy
Shipping Policy
Terms of Service
Contact us
About us
FUNanc!al distills the fun in finance and the finance in fun, makes news personal, and helps all reach happiness.